Published in Lab Business Week, June 3rd, 2007
Phase II, First Line, Colorectal Cancer Trial
To date, eight patients have been dosed in this trial, of which seven have stabilized disease. Two of the seven patients have tumor shrinkage, one of 40% (partial response according to RECIST) and one of 15%. The patients...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Lab Business Week